JP2021112211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021112211A5 JP2021112211A5 JP2021079698A JP2021079698A JP2021112211A5 JP 2021112211 A5 JP2021112211 A5 JP 2021112211A5 JP 2021079698 A JP2021079698 A JP 2021079698A JP 2021079698 A JP2021079698 A JP 2021079698A JP 2021112211 A5 JP2021112211 A5 JP 2021112211A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition
- composition according
- grna
- multicellular organism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020005004 Guide RNA Proteins 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 3
- 230000004807 localization Effects 0.000 claims 3
- 108091033409 CRISPR Proteins 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021141109A JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181162P | 2015-06-17 | 2015-06-17 | |
| US62/181,162 | 2015-06-17 | ||
| JP2018517674A JP2018521689A (ja) | 2015-06-17 | 2016-06-16 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517674A Division JP2018521689A (ja) | 2015-06-17 | 2016-06-16 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021141109A Division JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021112211A JP2021112211A (ja) | 2021-08-05 |
| JP2021112211A5 true JP2021112211A5 (enExample) | 2021-10-14 |
| JP7170090B2 JP7170090B2 (ja) | 2022-11-11 |
Family
ID=56292934
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517674A Ceased JP2018521689A (ja) | 2015-06-17 | 2016-06-16 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
| JP2021079698A Active JP7170090B2 (ja) | 2015-06-17 | 2021-05-10 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
| JP2021141109A Withdrawn JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517674A Ceased JP2018521689A (ja) | 2015-06-17 | 2016-06-16 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021141109A Withdrawn JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11473082B2 (enExample) |
| EP (2) | EP3310909B1 (enExample) |
| JP (3) | JP2018521689A (enExample) |
| KR (1) | KR102637402B1 (enExample) |
| CN (1) | CN108026519A (enExample) |
| AU (2) | AU2016278226B2 (enExample) |
| CA (1) | CA2989827C (enExample) |
| DK (1) | DK3310909T3 (enExample) |
| ES (1) | ES2886599T3 (enExample) |
| PT (1) | PT3310909T (enExample) |
| WO (1) | WO2016205554A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2891510C (en) | 2012-11-16 | 2022-10-18 | Transposagen Biopharmaceuticals, Inc. | Site-specific enzymes and methods of use |
| IL287561B2 (en) | 2014-10-01 | 2024-03-01 | Massachusetts Gen Hospital | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| KR102588469B1 (ko) * | 2016-09-30 | 2023-10-11 | 포세이다 테라퓨틱스, 인크. | 변형된 줄기세포 기억 t 세포, 이의 제조 방법 및 사용 방법 |
| KR102523318B1 (ko) | 2016-12-16 | 2023-04-18 | 비-모젠 바이오테크놀로지스, 인크. | 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법 |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| CN117959418A (zh) | 2017-03-13 | 2024-05-03 | 波赛达治疗公司 | 用于选择性消除和替换造血干细胞的组合物和方法 |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| SG11201911864PA (en) * | 2017-07-11 | 2020-01-30 | Sigma Aldrich Co Llc | Using nucleosome interacting protein domains to enhance targeted genome modification |
| US12227742B2 (en) | 2017-10-23 | 2025-02-18 | The Broad Institute, Inc. | Nucleic acid modifiers |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| WO2019126578A1 (en) * | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
| CA3104288A1 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| CN110938658B (zh) * | 2018-09-21 | 2023-02-07 | 中国科学院分子细胞科学卓越创新中心 | 一种抗体进化方法及其应用 |
| WO2020077360A1 (en) | 2018-10-12 | 2020-04-16 | Poseida Therapeutics, Inc. | Hematopoietic stem cell compositions, methods of making and method of use |
| CA3124103A1 (en) | 2018-12-20 | 2020-06-25 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| WO2020160481A1 (en) * | 2019-02-01 | 2020-08-06 | The General Hospital Corporation | Targetable 3'-overhang nuclease fusion proteins |
| CN113677694B (zh) * | 2019-04-09 | 2025-01-10 | 国立研究开发法人科学技术振兴机构 | 核酸结合蛋白 |
| JP2022536364A (ja) | 2019-06-13 | 2022-08-15 | ザ ジェネラル ホスピタル コーポレイション | 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法 |
| KR20220057596A (ko) | 2019-09-05 | 2022-05-09 | 포세이다 테라퓨틱스, 인크. | 동종이계 세포 조성물 및 사용 방법 |
| CA3162246A1 (en) | 2019-12-20 | 2021-06-24 | Poseida Therapeutics, Inc. | Anti-muc1 compositions and methods of use |
| US20230121433A1 (en) | 2020-03-11 | 2023-04-20 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| WO2022020800A2 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| WO2022087148A1 (en) | 2020-10-21 | 2022-04-28 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| WO2022087354A1 (en) * | 2020-10-23 | 2022-04-28 | Altius Institute For Biomedical Sciences | Cell permeable proteins for genome engineering |
| CN112750498B (zh) * | 2020-12-30 | 2022-06-24 | 同济大学 | 靶向逆转录引物结合位点从而抑制hiv病毒复制的方法 |
| MX2023009850A (es) | 2021-02-23 | 2023-08-29 | Poseida Therapeutics Inc | Composiciones y metodos para la administracion de acidos nucleicos. |
| EP4298205A1 (en) | 2021-02-23 | 2024-01-03 | Poseida Therapeutics, Inc. | Genetically modified induced pluripotent stem cells and methods of use thereof |
| US20240424097A1 (en) | 2021-09-09 | 2024-12-26 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| WO2023060088A1 (en) | 2021-10-04 | 2023-04-13 | Poseida Therapeutics, Inc. | Transposon compositions and methods of use thereof |
| WO2023141576A1 (en) | 2022-01-21 | 2023-07-27 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| WO2023164573A1 (en) * | 2022-02-23 | 2023-08-31 | Poseida Therapeutics, Inc. | Genetically modified cells and methods of use thereof |
| WO2023209649A1 (en) * | 2022-04-29 | 2023-11-02 | Seqirus, Inc. | Method of dna linearization |
| WO2024007010A2 (en) * | 2022-06-30 | 2024-01-04 | Demeetra Agbio, Inc. | Gene editing compositions and methods of use thereof |
| WO2024084025A1 (en) | 2022-10-21 | 2024-04-25 | Keygene N.V. | Rna transfection in plant cells with modified rna |
| EP4623073A2 (en) | 2022-11-21 | 2025-10-01 | Iovance Biotherapeutics, Inc. | Methods for assessing proliferation potency of gene-edited t cells |
| IL320733A (en) | 2022-11-21 | 2025-07-01 | Iovance Biotherapeutics Inc | Two-dimensional processes for expanding tumor-infiltrating lymphocytes and treatments thereof |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024121354A1 (en) | 2022-12-08 | 2024-06-13 | Keygene N.V. | Duplex sequencing with covalently closed dna ends |
| WO2024155931A1 (en) | 2023-01-20 | 2024-07-25 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| EP4652153A1 (en) | 2023-01-20 | 2025-11-26 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| CN121079404A (zh) | 2023-02-21 | 2025-12-05 | 波西达治疗公司 | 用于基因组编辑的组合物和方法 |
| WO2024178055A1 (en) * | 2023-02-21 | 2024-08-29 | Poseida Therapeutics, Inc. | Compositions and methods for genome editing |
| WO2024209000A1 (en) | 2023-04-04 | 2024-10-10 | Keygene N.V. | Linkers for duplex sequencing |
| WO2024238829A1 (en) | 2023-05-17 | 2024-11-21 | Poseida Therapeutics, Inc. | Compositions targeting hbg1 and hbg2 and methods of use thereof |
| WO2025049925A2 (en) | 2023-09-01 | 2025-03-06 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025096980A1 (en) * | 2023-11-02 | 2025-05-08 | Poseida Therapeutics, Inc. | Compositions targeting klkb1 and methods of use thereof |
| WO2025160432A1 (en) | 2024-01-26 | 2025-07-31 | Poseida Therapeutics, Inc. | Methods and compositions for enhancing in vivo persistence and potency of cell therapy |
| WO2025171237A1 (en) | 2024-02-08 | 2025-08-14 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025221789A1 (en) | 2024-04-16 | 2025-10-23 | Poseida Therapeutics, Inc. | Compositions and methods for use in car/tcr cell therapies |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5380831A (en) | 1986-04-04 | 1995-01-10 | Mycogen Plant Science, Inc. | Synthetic insecticidal crystal protein gene |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| TW261517B (enExample) | 1991-11-29 | 1995-11-01 | Mitsubishi Shozi Kk | |
| US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| US5645829A (en) | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US5714353A (en) | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| US5639642A (en) | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US7285416B2 (en) | 2000-01-24 | 2007-10-23 | Gendaq Limited | Regulated gene expression in plants |
| DE19524720A1 (de) | 1995-07-12 | 1997-01-16 | Hoechst Ag | Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3" |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| JP4216350B2 (ja) | 1994-09-19 | 2009-01-28 | 大日本住友製薬株式会社 | 動物細胞感染用の組換えｄｎａウイルスベクター |
| US5789147A (en) | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
| US5869040A (en) | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
| US5928914A (en) | 1996-06-14 | 1999-07-27 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Methods and compositions for transforming cells |
| WO2000002996A2 (en) | 1998-07-10 | 2000-01-20 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| CA2246005A1 (en) | 1998-10-01 | 2000-04-01 | Hsc Research And Development Limited Partnership | Hybrid genes for gene therapy in erythroid cells |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| JP2003500051A (ja) | 1999-05-25 | 2003-01-07 | パノラマ リサーチ，インコーポレイティド | 相互作用活性化タンパク質 |
| WO2001083793A2 (en) | 2000-04-28 | 2001-11-08 | Sangamo Biosciences, Inc. | Targeted modification of chromatin structure |
| EP1353941B1 (en) | 2001-01-22 | 2013-03-13 | Sangamo BioSciences, Inc. | Modified zinc finger binding proteins |
| WO2002099104A1 (fr) * | 2001-06-05 | 2002-12-12 | Pola Chemical Industries Inc. | Polypeptide destabilisant une proteine dans des cellules dans des conditions aerobies et adn codant pour ce polypeptide |
| US20030138850A1 (en) | 2001-10-18 | 2003-07-24 | Ekkehard Mossner | Selecting for antibody-antigen interactions in bacteria cells by employing a protein fragment complementation assay |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| ATE531796T1 (de) | 2002-03-21 | 2011-11-15 | Sangamo Biosciences Inc | Verfahren und zusammensetzungen zur verwendung von zinkfinger-endonukleasen zur verbesserung der homologen rekombination |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
| US8021849B2 (en) | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
| US20060252140A1 (en) | 2005-04-29 | 2006-11-09 | Yant Stephen R | Development of a transposon system for site-specific DNA integration in mammalian cells |
| US7790379B2 (en) | 2005-05-19 | 2010-09-07 | Universite De Geneve | Mapping of proteins along chromatin by chromatin cleavage |
| WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
| JP2007159512A (ja) | 2005-12-15 | 2007-06-28 | Institute Of Physical & Chemical Research | Ｉｉｓ型制限酵素を用いる翻訳終止コドンの除去方法 |
| ATE547123T1 (de) | 2006-04-21 | 2012-03-15 | Mab Factory Gmbh | Antikörper-rnase-konjugat |
| US8748146B2 (en) | 2007-04-19 | 2014-06-10 | Celexion, Llc | Engineered nucleases and their uses for nucleic acid assembly |
| JP2010538659A (ja) | 2007-09-17 | 2010-12-16 | アフォミックス コーポレイション | デュアルベイトレポーターを用いてｓｃＦｖスクリーニングにおける特異性を増大させる方法 |
| EP2401298A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
| RU2011137030A (ru) | 2009-03-11 | 2013-04-20 | УАЙТ ЭлЭлСи | Способы очистки малых модулярных иммунофармацевтических белков |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| JP6208580B2 (ja) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス， インコーポレイテッド | 新規のｄｎａ結合タンパク質及びその使用 |
| KR101556359B1 (ko) * | 2011-01-03 | 2015-10-01 | 주식회사 툴젠 | 디자인된 tal 이펙터 뉴클레아제를 통한 게놈 엔지니어링 |
| CA2821579C (en) | 2011-01-06 | 2019-01-22 | Complix Sa | Alphabody libraries and methods for producing the same |
| US9499592B2 (en) | 2011-01-26 | 2016-11-22 | President And Fellows Of Harvard College | Transcription activator-like effectors |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| EP2522726A1 (en) | 2011-05-12 | 2012-11-14 | Fundació Privada Centre de Regulació Genòmica (CRG) | Zinc finger nucleases for p53 editing |
| US20140201858A1 (en) | 2011-05-17 | 2014-07-17 | Transposagen Biopharmaceuticals, Inc | Methods for site-specific genetic modification in stem cells using xanthomonas tal nucleases (xtn) for the creation of model organisms |
| EP2718446A2 (en) | 2011-06-07 | 2014-04-16 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
| EP3434775B1 (en) * | 2011-06-07 | 2020-03-18 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Protein having nuclease activity, fusion proteins and uses thereof |
| JP2015500648A (ja) | 2011-12-16 | 2015-01-08 | ターゲットジーン バイオテクノロジーズ リミテッド | 所定の標的核酸配列を修飾するための組成物及び方法 |
| WO2013152220A2 (en) | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
| CA2874436A1 (en) | 2012-05-21 | 2013-11-28 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
| RS59199B1 (sr) * | 2012-05-25 | 2019-10-31 | Univ California | Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta |
| US9181535B2 (en) * | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| DK2911687T3 (da) | 2012-10-26 | 2019-05-13 | Univ Brussel Vrije | Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf |
| CA2891510C (en) | 2012-11-16 | 2022-10-18 | Transposagen Biopharmaceuticals, Inc. | Site-specific enzymes and methods of use |
| KR102479178B1 (ko) * | 2012-12-06 | 2022-12-19 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-기초된 유전체 변형과 조절 |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| WO2015021426A1 (en) * | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | A crispr/cas system-based novel fusion protein and its application in genome editing |
| EP3613854A1 (en) | 2014-03-05 | 2020-02-26 | National University Corporation Kobe University | Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same |
| US20170114149A1 (en) | 2014-06-17 | 2017-04-27 | Poseida Therapeutics, Inc. | Methods and compositions for in vivo non-covalent linking |
| WO2015195798A1 (en) * | 2014-06-17 | 2015-12-23 | Poseida Therapeutics, Inc. | A method for directing proteins to specific loci in the genome and uses thereof |
| CN104450785A (zh) | 2014-12-08 | 2015-03-25 | 复旦大学 | 使用编码靶向核酸内切酶附着体载体的基因组编辑方法及试剂盒 |
-
2016
- 2016-06-16 AU AU2016278226A patent/AU2016278226B2/en active Active
- 2016-06-16 WO PCT/US2016/037922 patent/WO2016205554A1/en not_active Ceased
- 2016-06-16 EP EP16733813.6A patent/EP3310909B1/en active Active
- 2016-06-16 EP EP21177979.8A patent/EP3929286A1/en active Pending
- 2016-06-16 CN CN201680047154.3A patent/CN108026519A/zh active Pending
- 2016-06-16 DK DK16733813.6T patent/DK3310909T3/da active
- 2016-06-16 KR KR1020187001436A patent/KR102637402B1/ko active Active
- 2016-06-16 ES ES16733813T patent/ES2886599T3/es active Active
- 2016-06-16 PT PT167338136T patent/PT3310909T/pt unknown
- 2016-06-16 CA CA2989827A patent/CA2989827C/en active Active
- 2016-06-16 JP JP2018517674A patent/JP2018521689A/ja not_active Ceased
- 2016-06-16 US US15/580,675 patent/US11473082B2/en active Active
-
2021
- 2021-05-10 JP JP2021079698A patent/JP7170090B2/ja active Active
- 2021-08-31 JP JP2021141109A patent/JP2021182942A/ja not_active Withdrawn
- 2021-10-18 AU AU2021250992A patent/AU2021250992B2/en active Active
-
2022
- 2022-08-25 US US17/822,240 patent/US20230257737A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021112211A5 (enExample) | ||
| GB2556276A (en) | Engineered crispr-CAS9 compositions and methods of use | |
| CY1121894T1 (el) | Θεραπεια hbv | |
| Brankovics et al. | Mitochondrial genomes reveal recombination in the presumed asexual Fusarium oxysporum species complex | |
| BR112022007481A2 (pt) | Lipídios ionizáveis e composições de nanopartículas dos mesmos | |
| Kawalek et al. | Rules and exceptions: the role of chromosomal ParB in DNA segregation and other cellular processes | |
| JP2019517268A5 (enExample) | ||
| SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
| EA202091673A1 (ru) | Способ амплификации нуклеиновых кислот | |
| WO2007047859A3 (en) | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity | |
| UA118014C2 (uk) | Спосіб модифікації днк-мішені | |
| JP2019508051A5 (enExample) | ||
| WO2017053431A3 (en) | Allele selective gene editing and uses thereof | |
| JP2018518163A5 (enExample) | ||
| BR0314138A (pt) | composição, e, método | |
| WO2017156311A3 (en) | Combination vectors and methods for treating cancer | |
| RU2022103641A (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
| JP2012505657A5 (enExample) | ||
| CN109963944A (zh) | 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA | |
| Liu et al. | Blossom of CRISPR technologies and applications in disease treatment | |
| JP2019537445A5 (enExample) | ||
| WO2019117660A3 (ko) | Crispr 시스템 기능 향상 방법 및 그의 이용 | |
| WO2023288304A3 (en) | Context-specific adenine base editors and uses thereof | |
| WO2020036654A3 (en) | Highly knotted molecular topologies from single-stranded nucleic acids | |
| BRPI0410951A (pt) | nucleotìdeos para prevenção e tratamento de patologias bacterianas e fungicas |